Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
0.9800
-0.0026 (-0.26%)
Aug 14, 2025, 11:38 AM - Market open
AKTX's stock price has decreased by -71.13% in the past year and price targets may not have had time to catch up.
Akari Therapeutics, Analyst Ratings
Total Analysts
1
Consensus Rating
Strong Buy
Price Target
$5.00
Upside
+410.20%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Initiates $5 | Strong Buy | Initiates | $5 | +410.20% | Jul 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +2,961.22% | Dec 5, 2022 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Initiates $80 | Strong Buy | Initiates | $80 | +8,063.27% | Nov 1, 2022 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $140 → $100 | Strong Buy | Maintains | $140 → $100 | +10,104.08% | Mar 13, 2020 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $300 → $160 | Strong Buy | Maintains | $300 → $160 | +16,226.53% | Mar 29, 2018 |
| B. Riley Securities | B. Riley Securities | Hold Initiates $60 | Hold | Initiates | $60 | +6,022.45% | Feb 8, 2018 |
| William Blair | William Blair | Hold → Buy Upgrades n/a | Hold → Buy | Upgrades | n/a | n/a | Sep 22, 2017 |
| Chardan Capital | Chardan Capital | Strong Sell → Hold Upgrades n/a | Strong Sell → Hold | Upgrades | n/a | n/a | May 31, 2017 |
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | May 12, 2017 |
| Chardan Capital | Chardan Capital | Strong Sell Reiterates $100 → $130 | Strong Sell | Reiterates | $100 → $130 | +13,165.31% | Apr 17, 2017 |
| Chardan Capital | Chardan Capital | Strong Sell Initiates $100 | Strong Sell | Initiates | $100 | +10,104.08% | Jul 11, 2016 |